Somatostatin Analogs for Pancreatic Neuroendocrine Tumors: Any Benefit When Ki‐67 Is ≥10%?

BACKGROUND: Long‐acting somatostatin analogs (SSAs) are the primary first‐line treatment of well‐differentiated advanced gastroenteropancreatic neuroendocrine tumors (NETs), but data about their efficacy in pancreatic NETs (panNETs) with Ki‐67 ≥10% are still limited. MATERIALS AND METHODS: To assess...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Oncologist
Prif Awduron: Merola, Elettra, Alonso Gordoa, Teresa, Zhang, Panpan, Al‐Toubah, Taymeyah, Pellè, Eleonora, Kolasińska‐Ćwikła, Agnieszka, Zandee, Wouter, Laskaratos, Faidon, de Mestier, Louis, Lamarca, Angela, Hernando, Jorge, Cwikla, Jaroslaw, Strosberg, Jonathan, de Herder, Wouter, Caplin, Martin, Cives, Mauro, van Leeuwaarde, Rachel
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: John Wiley & Sons, Inc. 2020
Pynciau:
Gastrointestinal Cancer
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC8018333/
https://ncbi.nlm.nih.gov/pubmed/33301235
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13633
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg